Schizophrenia, autoimmunity and immune system dysregulation: A comprehensive model updated and revisited

Journal of Autoimmunity

Volumn 27, Issue 2, 2006, Pages 71-80

  Strous, Rael D ^a   Shoenfeld, Yehuda ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Autoimmunity; Cytokines; Immunology; Lymphocytes; Schizophrenia

Indexed keywords

CORTICOSTEROID; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PENTOXIFYLLINE; TRANSFER FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AUTISM; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BLOOD BRAIN BARRIER; DATA BASE; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOTHERAPY; LYMPHOCYTE; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; THEORETICAL STUDY; UNSPECIFIED SIDE EFFECT;

ANIMALS; AUTOIMMUNITY; HUMANS; IMMUNE SYSTEM; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; SCHIZOPHRENIA; T-LYMPHOCYTES;

EID: 33749531529     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2006.07.006     Document Type: Review

References (106)

1. Freedman R. Schizophrenia. N Engl J Med 349 (2003) 1738-1749
2. Muller N., Riedel M., Ackenheil M., and Schwarz M.J. The role of immune function in schizophrenia: an overview. Eur Arch Psychiatry Clin Neurosci 249 (1999) 62-68
3. Naudin J., Capo C., Giusano B., Mege J.L., and Azorin J.M. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?. Schizophr Res 26 (1997) 227-233
4. Soliven B., and Albert J. Tumor necrosis factor modulates the inactivation of catecholamine secretion in cultured sympathetic neurons. J Neurochem 58 (1992) 1073-1078
5. Zalcman S., Green-Johnson J.M., Murray L., Nance D.M., Dyck D., Anisman H., et al. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res 643 (1994) 40-49
6. Kowalski J., Blada P., Kucia K., Madej A., and Herman Z.S. Neuroleptics normalize increased release of interleukin- 1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia. Schizophr Res 50 (2001) 169-175
7. Denicoff K.D., Rubinow D.R., Papa M.Z., Simpson C., Seipp C.A., Lotze M.T., et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 107 (1987) 293-300
8. Amital H., and Shoenfeld Y. Autoimmunity and schizophrenia: an epiphenomenon or an etiology?. Isr J Med Sci 29 (1993) 593-597
9. Mendelovic S., Doron A., and Shoenfeld Y. Schizophrenia-an autoimmune disease?. Harefuah (Hebrew) 133 (1997) 629-631
10. Rapaport M.H., and Delrahim K.K. An abbreviated review of immune abnormalities in schizophrenia. CNS Spectr 6 (2001) 392-397
11. Burch P.R. Schizophrenia: some new aetiological considerations. Br J Psychiatry 110 (1964) 818-824
12. Muller N., and Ackenheil M. Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: relationship to negative symptomatology. Schizophr Res 14 (1995) 223-228
13. Gilvarry C.M., Sham P.C., Jones P.B., Cannon M., Wright P., Lewis S.W., et al. Family history of autoimmune diseases in psychosis. Schizophr Res 19 (1996) 33-40
14. Gorwood P., Pouchot J., Vinceneux P., Puechal X., Flipo R.M., De Bandt M., et al. Club Rhumatisme et Inflammation. Rheumatoid arthritis and schizophrenia: a negative association at a dimensional level. Schizophr Res 66 (2004) 21-29
15. Torrey E.F., and Yolken R.H. The schizophrenia-rheumatoid arthritis connection: infectious, immune, or both?. Brain Behav Immun 15 (2001) 401-410
16. Fessel W.J., Hirata-Hibi M., and Shapiro I.M. Genetic and stress factors affecting the abnormal lymphocyte in schizophrenia. J Psychiatr Res 3 (1965) 275-283
17. Hirata-Hibi M., and Fessel W.J. The bone marrow in schizophrenia. Arch Gen Psychiatry 10 (1964) 414-419
18. Lin A., Kenis G., Bignotti S., Tura G.J., De Jong R., Bosmans E., et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 32 (1998) 9-15
19. Maes M., Bosmans E., Calabrese J., Smith R., and Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 29 (1995) 141-152
20. Ganguli R., Yang Z., Shurin G., Chengappa K.N., Brar J.S., Gubbi A.V., et al. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res 51 (1994) 1-10
21. Brett F.M., Mizisin A.P., Powell H.C., and Campbell I.L. Evolution of neuropathologic abnormalities associated with blood-brain barrier breakdown in transgenic mice expressing interleukin-6 in astrocytes. J Neuropathol Exp Neurol 54 (1995) 766-775
22. Gaughran F., O'Neill E., Cole M., Collins K., Daly R.J., and Shanahan F. Increased soluble interleukin 2 receptor levels in schizophrenia. Schizophr Res 29 (1998) 263-267
23. Rapaport M.H., and Lohr J.B. Serum-soluble interleukin-2 receptors in neuroleptic-naïve schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr Scand 90 (1994) 311-315
24. Rapaport M.H., Torrey E.F., McAllister C.G., Nelson D.L., Pickar D., and Paul S.M. Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins. Eur Arch Psychiatry Clin Neurosci 243 (1993) 7-10
25. Muller N., Riedel M., Hadjamu M., Schwarz M.J., Ackenheil M., and Gruber R. Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia. Am J Psychiatry 156 (1999) 634-636
26. Villemain F., Chatenoud L., Galinowski A., Homo-Delarche F., Ginestet D., Loo H., et al. Aberrant T cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production. Am J Psychiatry 146 (1989) 609-616
27. Rothermundt M., Arolt V., Weitzsch C., Eckhoff D., and Kirchner H. Production of cytokines in acute schizophrenic psychosis. Biol Psychiatry 40 (1996) 1294-1297
28. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y., and Shen Y.C. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiatry 65 (2004) 940-947
29. Cazzullo C.L., Scarone S., Grassi B., Vismara C., Trabattoni D., Clerici M., et al. Cytokines production in chronic schizophrenia patients with or without paranoid behaviour. Prog Neuropsychopharmacol Biol Psychiatry 22 (1998) 947-957
30. Mittleman B.B., Castellanos F.X., Jacobsen L.K., Rapoport J.L., Swedo S.E., and Shearer G.M. Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J Immunol 159 (1997) 2994-2999
31. Schwarz M.J., Riedel M., Ackenheil M., and Muller N. Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biol Psychiatry 47 (2000) 29-33
32. Kilidireas K., Latov N., Strauss D.H., Gorig A.D., Hashim G.A., Gorman J.M., et al. Antibodies to the human 60 kDa heat-shock protein in patients with schizophrenia. Lancet 340 (1992) 569-572
33. Schwarz M.J., Riedel M., Gruber R., Ackenheil M., and Muller N. Antibodies to heat shock proteins in schizophrenic patients: implications for the mechanism of the disease. Am J Psychiatry 156 (1999) 1103-1104
34. Avgustin B., Wraber B., and Tavcar R. Increased Th1 and Th2 immune reactivity with relative Th2 dominance in patients with acute exacerbation of schizophrenia. Croat Med J 46 (2005) 268-274
35. Riedel M, Spellmann I, Schwarz MJ, Strassnig M, Sikorski C, Moller HJ, et al. Decreased T cellular immune response in schizophrenic patients. J Psychiatr Res, in press. doi:10.1016/j.jpsychires.2005.11.007.
36. Rothermundt M., Arolt V., and Bayer T.A. Review of immunological and immunopathological findings in schizophrenia. Brain Behav Immun 15 (2001) 319-339
37. Lieberman J.A. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry 46 (1999) 729-739
38. Bayer T.A., Buslei R., Havas L., and Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci Lett 271 (1999) 126-128
39. Radewicz K., Garey L.J., Gentleman S.M., and Reynolds R. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J Neuropathol Exp Neurol 59 (2000) 137-150
40. Kuritzky A., Livni E., Munitz H., Englander T., Tyano S., Wijsenbeek H., et al. Cell-mediated immunity to human myelin basic protein in schizophrenic patients. J Neurol Sci 30 (1976) 369-373
41. Ruutiainen J., Arnadottir T., Molnar G., Salmi A., and Frey H. Myelin basic protein antibodies in the serum and CSF of multiple sclerosis and subacute sclerosing panencephalitis patients. Acta Neurol Scand 64 (1981) 196-206
42. Kirch D.G., Kaufmann C.A., Papadopoulos N.M., Martin B., and Weinberger D.R. Abnormal cerebrospinal fluid protein indices in schizophrenia. Biol Psychiatry 20 (1985) 1039-1046
43. Schwarz M.J., Riedel M., Gruber R., Muller N., and Ackenheil M. Autoantibodies against 60-kDa heat shock protein in schizophrenia. Eur Arch Psychiatry Clin Neurosci 248 (1998) 282-288
44. Eaton W.W., Byrne M., Ewald H., Mors O., Chen C.Y., Agerbo E., and Mortensen P.B. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry 163 (2006) 521-528
45. Kirch D.G. Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal. Schizophr Bull 19 (1993) 355-370
46. Chengappa K.N., Nimgaonkar V.L., Bachert C., Yang Z.W., Rabin B.S., and Ganguli R. Obstetric complications and autoantibodies in schizophrenia. Acta Psychiatr Scand 92 (1995) 270-273
47. Ashdown H., Dumont Y., Ng M., Poole S., Boksa P., and Luheshi G.N. The role of cytokines in mediating effects of prenatal infection on the fetus: implications for schizophrenia. Mol Psychiatry 11 (2006) 47-55
48. Insel B.J., Brown A.S., Bresnahan M.A., Schaefer C.A., and Susser E.S. Maternal-fetal blood incompatibility and the risk of schizophrenia in offspring. Schizophr Res 80 (2005) 331-342
49. Meyer U., Feldon J., Schedlowski M., and Yee B.K. Immunological stress at the maternal-foetal interface: a link between neurodevelopment and adult psychopathology. Brain Behav Immun 20 (2006) 378-388
50. Ozawa K., Hashimoto K., Kishimoto T., Shimizu E., Ishikura H., and Iyo M. Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry 59 (2006) 546-554
51. Torrey E.F., Miller J., Rawlings R., and Yolken R.H. Seasonality of births in schizophrenia and bipolar disorder: a review of the literature. Schizophr Res 28 (1997) 1-38
52. Brown A.S. Prenatal infection as a risk factor for schizophrenia. Schizophr Bull 32 (2006) 200-202
53. Bartova L., Rajcani J., and Pogady J. Herpes simplex virus antibodies in the cerebrospinal fluid of schizophrenic patients. Acta Virol 31 (1987) 443-446
54. Pelonero A.L., Pandurangi A.K., and Calabrese V.P. Serum IgG antibody to herpes viruses in schizophrenia. Psychiatry Res 33 (1990) 11-17
55. Pandurangi A.K., Pelonero A.L., Nadel L., and Calabrese V.P. Brain structure changes in schizophrenics with high serum titers of antibodies to herpes virus. Schizophr Res 11 (1994) 245-250
56. Albrecht P., Torrey E.F., Boone E., Hicks J.T., and Daniel N. Raised cytomegalovirus-antibody level in cerebrospinal fluid of schizophrenic patients. Lancet 2 (1980) 769-772
57. Torrey E.F., Yolken R.H., and Winfrey C.J. Cytomegalovirus antibody in cerebrospinal fluid of schizophrenic patients detected by enzyme immunoassay. Science 216 (1982) 892-894
58. Delisi L.E., Smith S.B., Hamovit J.R., Maxwell M.E., Goldin L.R., Dingman C.W., et al. Herpes simplex virus, cytomegalovirus and Epstein-Barr virus antibody titres in sera from schizophrenic patients. Psychol Med 16 (1986) 757-763
59. Torrey E.F., Rawlings R., and Waldman I.N. Schizophrenic births and viral diseases in two states. Schizophr Res 1 (1988) 73-77
60. Hart D.J., Heath R.G., Sautter Jr. F.J., Schwartz B.D., Garry R.F., Choi B., et al. Antiretroviral antibodies: implications for schizophrenia, schizophrenia spectrum disorders, and bipolar disorder. Biol Psychiatry 45 (1999) 704-714
61. Karlsson H., Bachmann S., Schroder J., McArthur J., Torrey E.F., and Yolken R.H. Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia. Proc Natl Acad Sci USA 98 (2001) 4634-4639
62. Chen C.H., Chiu Y.L., Wei F.C., Koong F.J., Liu H.C., Shaw C.K., et al. High seroprevalence of Borna virus infection in schizophrenic patients, family members and mental health workers in Taiwan. Mol Psychiatry 4 (1999) 33-38
63. Waltrip II R.W., Buchanan R.W., Carpenter Jr. W.T., Kirkpatrick B., Summerfelt A., Breier A., et al. Borna disease virus antibodies and the deficit syndrome of schizophrenia. Schizophr Res 23 (1997) 253-257
64. Chengappa K.N., Carpenter A.B., Keshavan M.S., Yang Z.W., Kelly R.H., Rabin B.S., et al. Elevated IGG and IGM anticardiolipin antibodies in a subgroup of medicated and unmedicated schizophrenic patients. Biol Psychiatry 30 (1991) 731-735
65. Firer M., Sirota P., Schild K., Elizur A., and Slor H. Anticardiolipin antibodies are elevated in drug-free, multiply affected families with schizophrenia. J Clin Immunol 14 (1994) 73-78
66. Ganguli R., Rabin B.S., and Brar J.S. Antinuclear and gastric parietal cell autoantibodies in schizophrenic patients. Biol Psychiatry 32 (1992) 735-738
67. Sirota P., Firer M.A., Schild K., Tanay A., Elizur A., Meytes D., et al. Autoantibodies to DNA in multicase families with schizophrenia. Biol Psychiatry 33 (1993) 450-455
68. Villemain F., Magnin M., Feuillet-Fieux M.N., Zarifian E., Loo H., and Bach J.F. Anti-histone antibodies in schizophrenia and affective disorders. Psychiatry Res 24 (1988) 53-60
69. Teplizki H.A., Sela B., and Shoenfeld Y. Autoantibodies to brain and polynucleotides in patients with schizophrenia: a puzzle. Immunol Res 11 (1992) 66-73
70. Kipnis J., Cardon M., Strous R.D., and Schwartz M. Loss of autoimmune T cells correlates with brain diseases: possible implications for schizophrenia?. Trends Mol Med 12 (2006) 107-112
71. Kipnis J., Cohen H., Cardon M., Ziv Y., and Schwartz M. T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. Proc Natl Acad Sci U S A 101 (2004) 8180-8185
72. Rasmussen H.B., Timm S., Wang A.G., Soeby K., Lublin H., Fenger M., et al. Association between the CCR5 32-bp deletion allele and late onset of schizophrenia. Am J Psychiatry 163 (2006) 507-511
73. Schwarz M.J., Kronig H., Riedel M., Dehning S., Douhet A., Spellmann I., et al. IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia. Eur Arch Psychiatry Clin Neurosci 256 (2006) 72-76
74. Kronig H., Riedel M., Schwarz M.J., Strassnig M., Moller H.J., Ackenheil M., et al. ICAM G241A polymorphism and soluble ICAM-1 serum levels: evidence for an active immune process in schizophrenia. Neuroimmunomodulation 12 (2005) 54-59
75. Yu L., Yang M.S., Zhao J., Shi Y.Y., Zhao X.Z., Yang J.D., et al. An association between polymorphisms of the interleukin-10 gene promoter and schizophrenia in the Chinese population. Schizophr Res 71 (2004) 179-183
76. Ilani T., Strous R.D., and Fuchs S. Dopaminergic regulation of immune cells via D3 dopamine receptor: a pathway mediated by activated T cells. FASEB J 18 (2004) 1600-1602
77. Vogel M., Busse S., Freyberger H.J., and Grabe H.J. Dopamine D3 receptor and schizophrenia: A widened scope for the immune hypothesis. Med Hypotheses 67 (2006) 354-358
78. Jones A.L., Mowry B.J., Pender M.P., and Greer J.M. Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis?. Immunol Cell Biol 83 (2005) 9-17
79. Zuckerman L., and Weiner I. Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. J Psychiatr Res 39 (2005) 311-323
80. Schulz S.C., van Kammen D.P., Waters R., Klein H.G., Balow J.E., and Bunney Jr. W.E. Double-blind evaluation of plasmapheresis in schizophrenic patients: a pilot study. Artif Organs 7 (1983) 317-321
81. Saunders J.C., and Muchmore E. Phenothiazine effect on human antibody synthesis. Br J Psychiatry 110 (1964) 84-89
82. Leykin I., Mayer R., and Shinitzky M. Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology 37 (1997) 75-86
83. Pollmacher T., Hinze-Selch D., Mullington J., and Holsboer F. Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors. Arch Gen Psychiatry 52 (1995) 877-878
84. Muller N., Hofschuster E., Ackenheil M., and Eckstein R. T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy. Acta Psychiatr Scand 87 (1993) 66-71
85. Muller N., Empl M., Riedel M., Schwarz M., and Ackenheil M. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur Arch Psychiatry Clin Neurosci 247 (1997) 308-313
86. Masserini C., Vita A., Basile R., Morselli R., Boato P., Peruzzi C., et al. Lymphocyte subsets in schizophrenic disorders. Relationship with clinical, neuromorphological and treatment variables. Schizophr Res 3 (1990) 269-275
87. Sirota P., Meiman M., Herschko R., and Bessler H. Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients. Psychiatry Res 134 (2005) 151-159
88. Skurkovich S., and Skurkovich B. Anticytokine therapy, especially anti-interferon-{gamma}, as a pathogenetic treatment in TH-1 autoimmune diseases. Ann NY Acad Sci 1051 (2005) 684-700
89. Sperner-Unterweger B. Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications. Drugs 65 (2005) 1493-1520
90. Skurkovich B., and Skurkovich S. Anti-interferon-gamma antibodies in the treatment of autoimmune diseases. Curr Opin Mol Ther 5 (2003) 52-57
91. Caruso A., and Turano A. Natural antibodies to interferon-gamma. Biotherapy 10 (1997) 29-37
92. Levy-Soussan P., Berneman A., Poirier M.F., Galinowski A., Loo H., Olie J.P., et al. Differences in the natural autoantibody patterns of patients with schizophrenia and normal individuals. J Psychiatry Neurosci 21 (1996) 89-95
93. Levine J., Susnovski M., Handzel Z.T., Leykin I., and Shinitzky M. Treatment of schizophrenia with an immunosuppressant. Lancet 344 (1994) 59-60
94. Muller N., Riedel M., and Schwarz M.J. Psychotropic effects of COX-2 inhibitors-a possible new approach for the treatment of psychiatric disorders. Pharmacopsychiatry 37 (2004) 266-269
95. Riedel M., Strassnig M., Schwarz M.J., and Muller N. COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date. CNS Drugs 19 (2005) 805-819
96. Brekke O.H., and Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2 (2003) 52-62
97. Ebert T., Chapman J., and Shoenfeld Y. Anti-ribosomal P-protein and its role in psychiatric manifestations of systemic lupus erythematosus: myth or reality?. Lupus 14 (2005) 571-575
98. Theodoropoulou S., Spanakos G., Baxevanis C.N., Economou M., Gritzapis A.D., Papamichail M.P., et al. Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophr Res 47 (2001) 13-25
99. O'Donnell M.C., Catts S.V., Ward P.B., Liebert B., Lloyd A., Wakefield D., et al. Increased production of interleukin-2 (IL-2) but not soluble interleukin-2 receptors (sIL-2R) in unmedicated patients with schizophrenia and schizophreniform disorder. Psychiatry Res 65 (1996) 171-178
100. McAllister C.G., van Kammen D.P., Rehn T.J., Miller A.L., Gurklis J., Kelley M.E., et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry 152 (1995) 1291-1297
101. Ganguli R., Brar J.S., Chengappa K.R., DeLeo M., Yang Z.W., Shurin G., et al. Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms. Arch Gen Psychiatry 52 (1995) 668-672
102. Kowalski J., Blada P., Kucia K., Lawniczek T., Madej A., Belowski D., et al. In-vitro immunomodulatory effects of haloperidol and perazine in schizophrenia. World J Biol Psychiatry 1 (2000) 190-196
103. Naudin J., Mege J.L., Azorin J.M., and Dassa D. Elevated circulating levels of IL-6 in schizophrenia. Schizophr Res 20 (1996) 269-273
104. Kim Y.K., Kim L., and Lee M.S. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res 44 (2000) 165-175
105. Kaminska T., Szuster-Ciesielska A., Wysocka A., Marmurowska-Michalowska H., Dubas-Slemp H., and Kandefer-Szerszen M. Serum cytokine level and production of reactive oxygen species (ROS) by blood neutrophils from a schizophrenic patient with hypersensitivity to neuroleptics. Med Sci Monit 9 (2003) CS71-CS75
106. Erbagci A.B., Herken H., Koyluoglu O., Yilmaz N., and Tarakcioglu M. Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators Inflamm 10 (2001) 109-115